The tuberculosis drug discovery and development pipeline and emerging drug targets

Cold Spring Harbor Perspectives in Biology

Volumn 7, Issue 5, 2015, Pages 1-25

  Mdluli, Khisimuzi ^a   Kaneko, Takushi ^a   Upton, Anna ^a  

^a GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYCOBACTERIUM TUBERCULOSIS;

EID: 84965189952     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a021154     Document Type: Article

References (198)

1. Abrahams GL, Kumar A, Savvi S, Hung AW, Wen S, Abell C, Barry CE III, Sherman DR, Boshoff HI, Mizrahi V. 2012a. Pathway-selective sensitization of Mycobacterium tuberculosis for target-based whole-cell screening. Chem Biol 19: 844–854.
2. Abrahams KA, Cox JA, Spivey VL, Loman NJ, Pallen MJ, Constantinidou C, Fernández R, Alemparte C, Remuiñán MJ, Barros D, et al. 2012b. Identification of novel im-idazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB. PLoS ONE 7: e52951.
3. Amaral L, Kristiansen JE, Abebe LS, Millett W. 1996. Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: Potential use for initial therapy of freshly diagnosed tuberculosis. J Antimicrob Chemother 38: 1049–1053.
4. Ananthan S, Faaleolea ER, Goldman RC, Hobrath JV, Kwong CD, Laughon BE, Maddry JA, Mehta A, Rasmus-sen L, Reynolds RC, et al. 2009. High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis (Edinb) 89: 334–353.
5. Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, et al. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307: 223–227.
6. Ballell L, Bates RH, Young RJ, Alvarez-Gomez D, Alvarez-Ruiz E, Barroso V, Blanco D, Crespo B, Escribano J, Gon-zález R, et al. 2013. Fueling open-source drug discovery: 177 Small-molecule leads against tuberculosis. Chem-MedChem 8: 313–321.
7. Ballell Pages L, Castro Pichel J, Fernandez Menendez R, Fernandez Velando EP, Gonzalez Del Valle S, Mendoza Losana A, Wolfendale MJ. 2010. (Pyrazol-3-yl)-1,3,4-thiadiazole-2-amine and(Pyrazol-3-yl)-1,3,4-thiazole-2-amine compounds. PCT publication No. WO 2010/118852 A1.
8. Batt SM, Jabeen T, Bhowruth V, Quill L, Lund PA, Eggeling L, Alderwick LJ, Fütterer K, Besra GS. 2012. Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors. Proc Natl Acad Sci 109: 11354–11359.
9. Beste DJ, Bonde B, Hawkins N, Ward JL, Beale MH, Noack S, Nöh K, Kruger NJ, Ratcliffe RG, McFadden J. 2011. 13C Metabolic flux analysis identifies an unusual route for pyruvate dissimilation in mycobacteria which requires isocitrate lyase and carbon dioxide fixation. PLoS Pathog 7: e1002091.
10. Bettencourt MV, Bosne-David S, Amaral L. 2000. Comparative in vitro activity of phenothiazines against multi-drug-resistant Mycobacterium tuberculosis. Int J Antimi-crob Agents 16: 69–71.
11. Bhat J, Narayan A, Venkatraman J, Chatterji M. 2013. LC-MS based assay to measure intracellular compound levels in Mycobacterium smegmatis: Linking compound levels to cellular potency. J Microbiol Methods 94: 152–158.
12. Brötz-Oesterhelt H, Beyer D, Kroll HP, Endermann R, Ladel C, Schroeder W, Hinzen B, Raddatz S, Paulsen H, Hen-ninger K, et al. 2005. Dysregulation of bacterial proteo-lytic machinery by a new class of antibiotics. Nat Med 11: 1082–1087.
13. Brown JR, North EJ, Hurdle JG, Morisseau C, Scarborough JS, Sun D, Korduláková J, Scherman MS, Jones V, Grze-gorzewicz A, et al. 2011. The structure-activity relationship of urea derivatives as anti-tuberculosis agents. Bioorg Med Chem 19: 5585–5595.
14. Brown DG, Lister T, May-Dracka TL. 2014. New natural products as new leads forantibacterial drug discovery. Bioorg Med Chem Lett 24: 413–418.
15. Bryk R, Griffin P, Nathan C. 2000. Peroxynitrite reductase activity of bacterial peroxiredoxins. Nature 407: 211–215.
16. Bryk R, Lima CD, Erdjument-Bromage H, Tempst P, Nathan C. 2002. Metabolic enzymes of mycobacteria linked to antioxidant defense byathioredoxin-like protein. Science 295: 1073–1077.
17. Bryk R, Gold B, Venugopal A, Singh J, Samy R, Pupek K, Cao H, Popescu C, Gurney M, Hotha S, et al. 2008. Selective killing of nonreplicating mycobacteria. Cell Host Microbe 3: 137–145.
18. Bryk R, Arango N, Venugopal A, Warren JD, Park YH, Patel MS, Lima CD, Nathan C. 2010. Triazaspirodimethoxy-benzoyls as selective inhibitors of mycobacterial lipoa-mide dehydrogenase. Biochemistry 49: 1616–1627.
19. Capyk JK, Casabon I, Gruninger R, Strynadka NC, Eltis LD. 2011. Activity of 3-ketosteroid 9a-hydroxylase (KshAB) indicates cholesterol side chain and ring degradation occur simultaneously in Mycobacterium tuberculosis. J Biol Chem 286: 40717–40724.
20. Casabon I, Crowe AM, Liu J, Eltis LD. 2013. FadD3 is an acyl-CoA synthetase that initiates catabolism of cholesterol rings C and D in actinobacteria. Mol Microbiol 87: 269–283.
21. Castro Pichel J, Fernandez Menendez R, Fernandez Velando EP, GonzalezDel Valle S, Mallo-Rubio A. 2012. 3-Amino-pyrazole derivatives useful against tuberculosis. PCT publication No. WO2012/049161.
22. Chang JC, Harik NS, Liao RP, Sherman DR. 2007. Identification of mycobacterial genes that alter growth and pathology in macrophages and in mice. J Infect Dis 196: 788–795.
23. Chang JC, Miner MD, Pandey AK, Gill WP, Harik NS, Sas-setti CM, Sherman DR. 2009. igr Genes and Mycobacte-rium tuberculosis cholesterol metabolism. J Bacteriol 191: 5232–5239.
24. Chen M, Borlak J, Tong W. 2013. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 58: 388–396.
25. Christophe T, Ewann F, Jeon HK, Cechetto J, Brodin P. 2010. High-content imaging of Mycobacterium tuberculosis-infected macrophages: An in vitro model for tuberculosis drug discovery. Future Med Chem 2: 1283–1293.
26. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE III, et al. 1998. Deciphering the biology of Mycobacterium tuber culosis from the complete genome sequence. Nature 393: 537–544.
27. Compton CL, Schmitz KR, Sauer RT, Sello JK. 2013. Antibacterial activity of and resistance to small molecule inhibitors of the ClpP peptidase. ACS Chem Biol 8: 2669–2677.
28. Conlon BP, Nakayasu ES, Fleck LE, LaFleur MD, Isabella VM, Coleman K, Leonard SN, Smith RD, Adkins JN, Lewis K. 2013. Activated ClpP kills persisters and eradicates a chronic biofilm infection. Nature 503: 365–370.
29. Cox JS, Chen B, McNeil M, Jacobs WR Jr. 1999. Complex lipid determines tissue-specific replication of Mycobacte-rium tuberculosis in mice. Nature 402: 79–83.
30. Darby CM, Ingólfsson HI, Jiang X, Shen C, Sun M, Zhao N, Burns K, Liu G, Ehrt S, Warren JD, et al. 2013. Whole cell screen for inhibitors of pH homeostasis in Mycobacteri-um tuberculosis. PLoS ONE 8: e68942.
31. Dartois V, Barry CEIII. 2013.Amedicinal chemists’ guide to the unique difficulties of lead optimization for tuberculosis. Bioorg Med Chem Lett 23: 4741–4750.
32. Debnath J, Siricilla S, Wan B, Crick DC, Lenaerts AJ, Franz-blau SG, Kurosu M. 2012. Discovery of selective mena-quinone biosynthesis inhibitors against Mycobacterium tuberculosis. J Med Chem 55: 3739–3755.
33. de Carvalho LP, Fischer SM, Marrero J, Nathan C, Ehrt S, Rhee KY. 2010. Metabolomics of Mycobacterium tuberculosis reveals compartmentalized co-catabolism of carbon substrates. Chem Biol 17: 1122–1131.
34. Dhiman RK, Mahapatra S, Slayden RA, Boyne ME, Lenaerts A, Hinshaw JC, Angala SK, Chatterjee D, Biswas K, Nar-ayanasamy P, et al. 2009. Menaquinone synthesis is critical for maintaining mycobacterial viability during exponential growth and recovery from non-replicating persistence. Mol Microbiol 72: 85–97.
35. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Church-yard G, et al. 2009. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360: 2397–2405.
36. Doherty CP. 2007. Host-pathogen interactions: The role of iron. J Nutr 137: 1341–1344.
37. Domann FE. 2013. Aberrant free radical biology is a unifying theme in the etiology and pathogenesis of major human diseases. Int J Mol Sci 14: 8491–8495.
38. Domenech P, Reed MB, Dowd CS, Manca C, Kaplan G, Barry CE III. 2004. The role of MmpL8 in sulfatide biogenesis and virulence of Mycobacterium tuberculosis. J Biol Chem 279: 21257–21265.
39. Domenech P, Reed MB, Barry CE III. 2005. Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance. Infect Immun 73: 3492–3501.
40. Dresen C, Lin LY, D’Angelo I, Tocheva EI, Strynadka N, Eltis LD. 2010. A flavin-dependent monooxygenase from My-cobacterium tuberculosis involved in cholesterol catabo-lism. J Biol Chem 285: 22264–22275.
41. Dwyer DJ, Kohanski MA, Collins JJ. 2009. Role of reactive oxygen species in antibiotic action and resistance. Curr Opin Microbiol 12: 482–489.
42. Encinas L, O’Keefe H, Neu M, Remuiñán MJ, Patel AM, Guardia A, Davie CP, Pérez-Macías N, Yang H, Convery MA, et al. 2014. Encoded library technology as a source of hits for the discoveryand lead optimization of a potent and selective class of bactericidal direct inhibitors of My-cobacterium tuberculosis InhA. J Med Chem 57: 1276–1288.
43. Engelhart CA, Aldrich CC. 2013. Synthesis of chromone, quinolone, and benzoxazinone sulfonamide nucleosides as conformationally constrained inhibitors of adenylat-ing enzymes required for siderophore biosynthesis. J Org Chem 78: 7470–7481.
44. Eoh H, Rhee KY. 2013. Multifunctional essentiality of suc-cinate metabolism in adaptation to hypoxia in Mycobac-terium tuberculosis. Proc Natl Acad Sci 110: 6554–6559.
45. Estorninho M, Smith H, Thole J, Harders-Westerveen J, Kierzek A, Butler RE, Neyrolles O, Stewart GR. 2010. ClgR regulation of chaperone and protease systems is essential for Mycobacterium tuberculosis parasitism of the macrophage. Microbiology 156: 3445–3455.
46. Feher M, Schmidt JM. 2003. Property distributions: Differences between drugs, natural products, and molecules from combinatorial chemistry. J Chem Inf Comput Sci 43: 218–227.
47. Finn J. 2012. Application of SBDD to the discovery of new antibacterial drugs. Methods Mol Biol 841: 291–319.
48. García A, Bocanegra-García V, Palma-Nicolás JP, Rivera G. 2012. Recent advances in antitubercular natural products. Eur J Med Chem 49: 1–23.
49. Gatfield J, Pieters J. 2000. Essential role for cholesterol in entry of mycobacteria into macrophages. Science 288: 1647–1650.
50. Gavrish E, Sit CS, Cao S, Kandror O, Spoering A, Peoples A, Ling L, Fetterman A, Hughes D, Bissell A, et al. 2014. Lassomycin, a ribosomally synthesized cyclic peptide, kills Mycobacterium tuberculosis by targeting the ATP-dependent protease ClpC1P1P2. Chem Biol 21: 509–518.
51. Gengenbacher M, Rao SP, Pethe K, Dick T. 2010. Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability. Microbiology 156: 81–87.
52. Goldman RC. 2013. Why are membrane targets discovered by phenotypic screens and genome sequencing in Myco-bacterium tuberculosis? Tuberculosis (Edinb) 93: 569–588.
53. Gould TA, van de Langemheen H, Muñoz-Elías EJ, McKin-ney JD, Sacchettini JC. 2006. Dual role of isocitrate lyase 1 in the glyoxylate and methylcitrate cycles in Mycobacte-rium tuberculosis. Mol Microbiol 61: 940–947.
54. Grant SS, Kaufmann BB, Chand NS, Haseley N, Hung DT. 2012. Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals. Proc Natl Acad Sci 109: 12147–12152.
55. Griffin JE, Gawronski JD, Dejesus MA, Ioerger TR, Akerley BJ, Sassetti CM. 2011. High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism. PLoS Pathog 7: e1002251.
56. Grzegorzewicz AE, Pham H, Gundi VA, Scherman MS, North EJ, Hess T, Jones V, Gruppo V, Born SE, Kordulá-ková J, et al. 2012a. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat Chem Biol 8: 334–341.
57. Grzegorzewicz AE, Korduláková J, Jones V, Born SE, Belar-dinelli JM, Vaquie´ A, Gundi VA, Madacki J, Slama N, Laval F, et al. 2012b. Acommon mechanism of inhibition of the Mycobacterium tuberculosis mycolic acid biosyn-thetic pathway by isoxyl and thiacetazone. J Biol Chem 287: 38434–38441.
58. Gupta V, Gupta RK, Khare G, Salunke DM, Tyagi AK. 2008. Cloning, expression, purification,crystallization and preliminary X-ray crystallographic analysis of bacterioferri-tin A from Mycobacterium tuberculosis. Acta Crystallogr Sect F Struct Biol Cryst Commun 64: 398–401.
59. Gurumurthy M, Rao M, Mukherjee T, Rao SP, Boshoff HI, Dick T, Barry CE III, Manjunatha UH. 2013. A novel F(420)-dependent anti-oxidant mechanism protects Mycobacterium tuberculosis against oxidative stress and bactericidal agents. Mol Microbiol 87: 744–755.
60. Guzman JD, Gupta A, Bucar F, Gibbons S, Bhakta S. 2012. Antimycobacterials from natural sources: Ancient times, antibiotic era and novel scaffolds. Front Biosci (Landmark Ed) 17: 1861–1881.
61. Hartkoorn RC, Sala C, Neres J, Pojer F, Magnet S, Mukherjee R, Uplekar S, Boy-Röttger S, Altmann KH, Cole ST. 2012. Towards a new tuberculosis drug: Pyridomycin—Na-ture’s isoniazid. EMBO Mol Med 4: 1032–1042.
62. Hartkoorn RC, Pojer F, Read JA, Gingell H, Neres J, Hor-lacher OP, Altmann KH, Cole ST. 2013. Pyridomycin bridges the NADH- and substrate-binding pockets of the enoyl reductase InhA. Nat Chem Biol 10: 96–98.
63. Holmes MA, Paulsene W, Jide X, Ratledge C, Strong RK. 2005. Siderocalin (Lcn 2) also binds carboxymycobac-tins, potentially defending against mycobacterial infections through iron sequestration. Structure 13: 29–41.
64. Höner Zu Bentrup K, Miczak A, Swenson DL, Russell DG. 1999. Characterization of activity and expression of iso-citrate lyase in Mycobacterium avium and Mycobacterium tuberculosis. J Bacteriol 181: 7161–7167.
65. Hung AW, Silvestre HL, Wen S, Ciulli A, Blundell TL, Abell C. 2009. Application of fragment growing and fragment linking to the discovery of inhibitors of Mycobacterium tuberculosis pantothenate synthetase. Angew Chem Int Ed Engl 48: 8452–8456.
66. Ingvarsson H, Maté MJ, Högbom M, Portnöı D, Benaroudj N, Alzari PM, Ortiz-Lombardía M, Unge T. 2007. Insights into the inter-ring plasticity of caseinolytic proteases from the X-ray structure of Mycobacterium tuberculosis ClpP1. Acta CrystallogrD Biol Crystallogr 63: 249–259.
67. Ioerger TR, O’Malley T, Liao R, Guinn KM, Hickey MJ, Mohaideen N, Murphy KC, Boshoff HI, Mizrahi V, Rubin EJ, et al. 2013. Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis. PLoS ONE 8: e75245.
68. Irschik H, Reichenbach H, Höfle G, Jansen R. 2007. The thuggacins, novel antibacterial macrolides from Soran-gium cellulosum acting against selected Gram-positive bacteria. J Antibiot (Tokyo) 60: 733–738.
69. Ishizaki Y, Hayashi C, Inoue K, Igarashi M, Takahashi Y, Pujari V, Crick DC, Brennan PJ, Nomoto A. 2013. Inhibition of the first step in synthesis of the mycobacterial cell wall core, catalyzed by the GlcNAc-1-phosphate transferase WecA, by the novel caprazamycin derivative CPZEN-45. J Biol Chem 288: 30309–30319.
70. Iwatsuki M, Tomoda H, Uchida R, Gouda H, Hirono S, Omura S. 2006. Lariatins, antimycobacterial peptides produced by Rhodococcus sp. K01-B0171, have a lasso structure. J Am Chem Soc 128: 7486–7491.
71. Iwatsuki M, Uchida R, Takakusagi Y, Matsumoto A, Jiang CL, Takahashi Y, Arai M, Kobayashi S, Matsumoto M, Inokoshi J, etal. 2007. Lariatins, novel anti-mycobacterial peptides with a lasso structure, produced by Rhodococcus jostii K01-B0171. J Antibiot (Tokyo) 60: 357–363.
72. Jain M, Cox JS. 2005. Interaction between polyketide synthase and transporter suggests coupled synthesis and export of virulence lipid in M. tuberculosis. PLoS Pathog 1: e2.
73. Johnson EE, Wessling-Resnick M. 2012. Iron metabolism and the innate immune response to infection. Microbes Infect 14: 207–216.
74. Jones CM, Niederweis M. 2011. Mycobacterium tuberculosis can utilize heme as an iron source. J Bacteriol 193: 1767–1770.
75. Jones CM, Wells RM, Madduri AV, Renfrow MB, Ratledge C, Moody DB, Niederweis M. 2014. Self-poisoning of Mycobacterium tuberculosis by interrupting siderophore recycling. Proc Natl Acad Sci 111: 1945–1950.
76. Kalscheuer R, Jacobs WR Jr. 2010. The significance of GlgE as a new target for tuberculosis. Drug News Perspect 23: 619–624.
77. Kana BD, Weinstein EA, Avarbock D, Dawes SS, Rubin H, Mizrahi V. 2001. Characterization of the cydAB-encoded cytochrome bd oxidase from Mycobacterium smegmatis. J Bacteriol 183: 7076–7086.
78. Kauffmann SHE. 2004. New issues in tuberculosis. Ann Rheum Dis 63: 1150–1156.
79. Kawate T, Iwase N, Shimizu M, Stanley SA, Wellington S, Kazyanskaya E, Hung DT. 2013. Synthesis and structure-activity relationships of phenyl-substituted coumarins with anti-tubercular activity that target FadD32. Bioorg Med Chem Lett 23: 6052–6059.
80. Keren I, Wu Y, Inocencio J, Mulcahy LR, Lewis K. 2013. Killing by bactericidal antibiotics does not depend on reactive oxygen species. Science 339: 1213–1216.
81. Kim MJ, Wainwright HC, Locketz M, Bekker LG, Walther GB, Dittrich C, Visser A, Wang W, Hsu FF, Wiehart U, et al. 2010. Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Mol Med 2: 258–274.
82. Kirst HA. 2013. Developing new antibacterials through natural product research. Expert Opin Drug Discov 8: 479–493.
83. Kirstein J, Hoffmann A, Lilie H, Schmidt R, Rübsamen-Waigmann H, Brötz-Oesterhelt H, Mogk A, Turgay K. 2009. The antibiotic ADEP reprogrammes ClpP, switching it from a regulated to an uncontrolled protease. EMBO Mol Med 1: 37–49.
84. Kjellsson MC, Via LE, Goh A, Weiner D, Low KM, Kern S, Pillai G, Barry CE III, Dartois V. 2012. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob Agents Chemo-ther 56: 446–457.
85. Kondreddi RR, Jiricek J, Rao SPS, Lakshminarayana SB, Camacho LR, Rao R, Herve M, Bifani P, Ma NL, Kuhen K, etal. 2013. Design, synthesis, and biological evaluation of indole-2-carboxamides: A promising class of antitu-berculosis agents. J Med Chem 56: 8849–8859.
86. Koul A, Vranckx L, Dendouga N, Balemans W, Van den Wyngaert I, Vergauwen K, Göhlmann HW, Willebrords R, Poncelet A, Guillemont J, et al. 2008. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem 283: 25273–25280.
87. Krátký M, Vinšová J. 2012. Advances in mycobacterial iso-citrate lyase targeting and inhibitors. Curr Med Chem 19: 6126–6137.
88. Krieger IV, Freundlich JS, Gawandi VB, Roberts JP, Gawandi VB, Sun Q, Owen JL, Fraile MT, Huss SI, Lavandera JL, et al. 2012. Structure-guided discovery of phenyl-diketo acids as potent inhibitors of M. tuberculosis malate synthase. Chem Biol 19: 1556–1567.
89. Kumar A, Casey A, Odingo J, Kesicki EA, Abrahams G, Vieth M, Masquelin T, Mizrahi V, Hipskind PA, Sherman DR, et al. 2013. A high-throughput screen against pantothe-nate synthetase (PanC) identifies 3-biphenyl-4-cyano- pyrrole-2-carboxylic acids as a new class of inhibitor with activity against Mycobacterium tuberculosis. PLoS ONE 8: e72786.
90. Kurosu M, Crick DC. 2009. MenA is apromising drug target for developing novel lead molecules to combat Mycobac-terium tuberculosis. Med Chem 5: 197–207.
91. Kurosu M, Narayanasamy P, Biswas K, Dhiman R, Crick DC. 2007. Discovery of 1,4-dihydroxy-2-naphthoate prenyl-transferase inhibitors: New drug leads for multidrug-re-sistant Gram-positive pathogens. J Med Chem 50: 3973–3974.
92. Lack NA, Yam KC, Lowe ED, Horsman GP, Owen RL, Sim E, Eltis LD. 2010. Characterization of a carbon-carbon hy-drolase from Mycobacterium tuberculosis involved in cholesterol metabolism. J Biol Chem 285: 434–443.
93. Lamichhane G, Tyagi S, Bishai WR. 2005. Designer arrays for defined mutant analysis to detect genes essential for survival of Mycobacterium tuberculosis in mouse lungs. Infect Immun 73: 2533–2540.
94. La Rosa V, Poce G, Canseco JO, Buroni S, Pasca MR, Biava M, Raju RM, Porretta GC, Alfonso S, Battilocchio C, et al. 2012. MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob Agents Chemother 56: 324–331.
95. Li JW, Vederas JC. 2009. Drug discovery and natural products: End of an era or an endless frontier? Science 325: 161–165.
96. Li X, Liu N, Zhang H, Knudson SE, Li HJ, Lai CT, Simmerl-ing C, Slayden RA, Tonge PJ. 2011. CoA Adducts of 4-Oxo-4-Phenylbut-2-enoates: Inhibitors of MenB from the M. tuberculosis menaquinone biosynthesis pathway. ACS Med Chem Lett 2: 818–823.
97. Li K, Schurig-Briccio LA, Feng X, Upadhyay A, Pujari V, Lechartier B, Fontes FL, Yang H, Rao G, Zhu W, et al. 2014. Multitarget drug discovery for tuberculosis and other infectious diseases. J Med Chem 57: 3126–3139.
98. Lin PL, Ford CB, Coleman MT, Myers AJ, Gawande R, Ioerger T, Sacchettini J, Fortune SM, Flynn JL. 2014. Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat Med 20: 75–79.
99. Liu K, Yu J, Russell DG. 2003. pckA-Deficient Mycobacteri-um bovis BCG shows attenuated virulence in mice and in macrophages. Microbiology 149: 1829–1835.
100. Lu XI, Zhou R, Sharma I, Li X, Kumar G, Swaminathan S, Tonge PJ, Tan DS. 2012. Stable analogues of OSB-AMP: Potent inhibitors of MenE, the o-succinatebenzoate-CoA synthetase from bacterial menaquinone biosynthesis. Chembiochem 13: 129–136.
101. Maddry JA, Ananthan S, Goldman RC, Hobrath JV, Kwong CD, Maddox C, Rasmussen L, Reynolds RC, Secrist JAIII, Sosa MI, et al. 2009. Antituberculosis activity of the molecular libraries screening center network library. Tuberculosis (Edinb) 89: 354–363.
102. Mai D, Jones J, Rodgers JW, Hartman JL IV, Kutsch O, Steyn AJ. 2011. A screen to identify small molecule inhibitors of protein-protein interactions in mycobacteria. Assay Drug Dev Technol 9: 299–310.
103. Mak PA, Rao SP, Ping Tan M, Lin X, Chyba J, Tay J, Ng SH, Tan BH, Cherian J, Duraiswamy J, et al. 2012a. A high-throughput screen to identify inhibitors of ATP homeo- stasis in non-replicating Mycobacterium tuberculosis. AC S Chem Biol 7: 1190–1197.
104. Manina G, McKinney JD. 2013. A single-cell perspective on non-growing but metabolically active (NGMA) bacteria. Curr Top Microbiol Immunol 374: 135–161.
105. Marrero J, Rhee KY, Schnappinger D, Pethe K, Ehrt S. 2010. Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection. Proc Natl Acad Sci 107: 9819–9824.
106. Marrero J, Trujillo C, Rhee KY, Ehrt S. 2013. Glucose phos-phorylation is required for Mycobacterium tuberculosis persistence in mice. PLoS Pathog 9: e1003116.
107. Matsoso LG, Kana BD, Crellin PK, Lea-Smith DJ, Pelosi A, Powell D, Dawes SS, Rubin H, Coppel RL, Mizrahi V. 2005. Function of the cytochrome bc1-aa3 branch of the respiratory network in mycobacteria and network adaptation occurring in response to its disruption. J Bac-teriol 187: 6300–6308.
108. McAdam RA, Quan S, Smith DA, Bardarov S, Betts JC, Cook FC, Hooker EU, Lewis AP, Woollard P, Everett MJ, et al. 2002. Characterization of a Mycobacterium tuberculosis H37Rv transposon library reveals insertions in 351 ORFs and mutants with altered virulence. Microbiology 148: 2975–2986.
109. McKinney JD, Höner zuBentrup K, Muñoz-Elías EJ, Miczak A, Chen B, Chan WT, Swenson D, Sacchettini JC, Jacobs WR Jr, Russell DG. 2000. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyox-ylate shunt enzyme isocitrate lyase. Nature 406: 735–738.
110. McMath LM, Habel JE, Sankaran B, Yu M, Hung LW, Gould-ing CW. 2010.Crystallization and preliminary X-raycrys-tallographic analysis of a Mycobacterium tuberculosis fer-ritin homolog, BfrB. Acta Crystallogr Sect F Struct Biol Cryst Commun 66: 1657–1661.
111. Milano A, Pasca MR, Provvedi R, Lucarelli AP, Manina G, Ribeiro AL, Manganelli R, Riccardi G. 2009. Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system. Tuberculosis (Edinb) 89: 84–90.
112. Miner MD, Chang JC, Pandey AK, Sassetti CM, Sherman DR. 2009. Role of cholesterol in Mycobacterium tuberculosis infection. Indian J Exp Biol 47: 407–411.
113. Mohn WW, van der Geize R, Stewart GR, Okamoto S, Liu J, Dijkhuizen L, Eltis LD. 2008. The actinobacterial mce4 locus encodes a steroid transporter. J Biol Chem 283: 35368–35374.
114. Monfeli RR, Beeson C. 2007. Targeting iron acquisition by Mycobacterium tuberculosis. Infect Disord Drug Targets 7: 213–220.
115. Moraski GC, Markley LD, Hipskind PA, Boshoff H, Cho S, Franzblau SG, Miller MJ. 2011. Advent of Imidazo[1,2-a]pyridine-3-carboxamides with potent multi- and extended drug resistant antituberculosis activity. ACS Med Chem Lett 2: 466–470.
116. Moraski GC, Markley LD, Chang M, Cho S, Franzblau SG, Hwang CH, Boshoff H, Miller MJ. 2012. Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thia-zoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds. Bioorg Med Chem 20: 2214–2220.
117. Muñoz-Elías EJ, McKinney JD. 2005. Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nat Med 11: 638–644.
118. Muñoz-Elías EJ, Upton AM, Cherian J, McKinney JD. 2006. Role of the methylcitrate cycle in Mycobacterium tuberculosis metabolism, intracellular growth, and virulence. Mol Microbiol 60: 1109–1122.
119. Mukhopadhyay B, Concar EM, Wolfe RS. 2001. A GTP-de-pendent vertebrate-type phosphoenolpyruvate carboxy-kinase from Mycobacterium smegmatis. J Biol Chem 276: 16137–16145.
120. Naven RT, Swiss R, Klug-McLeod J, Will Y, Greene N. 2013. The development of structure-activity relationships for mitochondrial dysfunction: Uncoupling of oxidative phosphorylation. Toxicol Sci 131: 271–278.
121. Neres J, Labello NP, Somu RV, Boshoff HI, Wilson DJ, Van-nada J, Chen L, Barry CE III, Bennett EM, Aldrich CC. 2008. Inhibition of siderophore biosynthesis in Mycobac-terium tuberculosis with nucleoside bisubstrate analogues: Structure-activity relationships of the nucleobase domain of 50 -O-[N-(salicyl)sulfamoyl]adenosine. J Med Chem 51: 5349–5370.
122. Nesbitt NM, Yang X, Fontán P, Kolesnikova I, Smith I, Sampson NS, Dubnau E. 2010. A thiolase of Mycobacte-rium tuberculosisisrequired forvirulence and production of androstenedione and androstadienedione from cholesterol. Infect Immun 78: 275–282.
123. Newman DJ, Cragg GM. 2012. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 75: 311–335.
124. Ollinger J, O’Malley T, Kesicki EA, Odingo J, Parish T. 2012. Validation of the essential ClpP protease in Mycobacteri-um tuberculosis as a novel drug target. J Bacteriol 194: 663–668.
125. Orme IM. 2014. A new unifying theory of the pathogenesis of tuberculosis. Tuberculosis (Edinb) 94: 8–14.
126. Owens CP, Chim N, Graves AB, Harmston CA, Iniguez A, Contreras H, Liptak MD, Goulding CW. 2013. The My-cobacterium tuberculosis secreted protein Rv0203 transfers hemetomembraneproteins MmpL3andMmpL11. J Biol Chem 288: 21714–21728.
127. Pai SR, Actor JK, Sepulveda E, Hunter RL Jr, Jagannath C. 2000. Identification of viable and non-viable Mycobacte-rium tuberculosis in mouse organs by directed RT-PCR for antigen 85B mRNA. Microb Pathog 28: 335–342.
128. Pan P, Tonge PJ. 2012. Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds. Curr Top Med Chem 12: 672–693.
129. Pandey AK, Sassetti CM. 2008. Mycobacterial persistence requires the utilization of host cholesterol. Proc Natl Acad Sci 105: 4376–4380.
130. Pandey R, Rodriguez GM. 2012. A ferritin mutant of Myco-bacterium tuberculosis is highly susceptible to killing by antibiotics and is unable to establish a chronic infection in mice. Infect Immun 80: 3650–3659.
131. Paulsen IT, Brown MH, Skurray RA. 1996. Proton-dependent multidrug efflux systems. Microbiol Rev 60: 575–608.
132. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. 2007. Drugs for bad bugs: Confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6: 29–40.
133. Pethe K, Bifani P, Jang J, Kang S, Park S, Ahn S, Jiricek J, Jung J, Jeon HK, Cechetto J, et al. 2013. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med 19: 1157–1160.
134. Peyron P, Bordier C, N’Diaye EN, Maridonneau-Parini I. 2000. Nonopsonic phagocytosis of Mycobacterium kan-sasii by human neutrophils depends on cholesterol and is mediated by CR3 associated with glycosylphosphati-dylinositol-anchored proteins. J Immunol 165: 5186– 5191.
135. Pruksakorn P, Arai M, Kotoku N, Vilchèze C, Baughn AD, Moodley P, Jacobs WR Jr, Kobayashi M. 2010. Trichoder-ins, novel aminolipopeptides from a marine sponge-derived Trichoderma sp., are active against dormant myco-bacteria. Bioorg Med Chem Lett 20: 3658–3663.
136. Pruksakorn P, Arai M, Liu L, Moodley P, Jacobs WR Jr, Kobayashi M. 2011. Action-mechanism of trichoderin A, an anti-dormant mycobacterial aminolipopeptide from marine sponge-derived Trichoderma sp. Biol Pharm Bull 34: 1287–1290.
137. Putman M, van Veen HW, Konings WN. 2000. Molecular properties of bacterial multidrug transporters. Microbiol Mol Biol Rev 64: 672–693.
138. Ramachandran S, Panda M, Mukherjee K, Choudhury NR, Tantry SJ, Kedari CK, Ramachandran V, Sharma S, Ra-mya VK, Guptha S, et al. 2013. Synthesis and structure activity relationship of imidazo[1,2-a]pyridine-8-car-boxamides as a novel antimycobacterial lead series. Bio-org Med Chem Lett 23: 4996–5001.
139. Rao SP, Alonso S, Rand L, Dick T, Pethe K. 2008. The proton motive force is required for maintaining ATP homeosta-sis and viability of hypoxic, nonreplicating Mycobacteri-um tuberculosis. Proc Natl Acad Sci 105: 11945–11950.
140. Rao SP, Lakshminarayana SB, Kondreddi RR, Herve M, Ca-macho LR, Bifani P, Kalapala SK, Jiricek J, Ma NL, Tan BH, et al. 2013. Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis. Sci Transl Med 5: 214ra168.
141. Ratledge C, Dover LG. 2000. Iron metabolism in pathogenic bacteria. Annu Rev Microbiol 54: 881–941.
142. Reddy PV, Puri RV, Khera A, Tyagi AK. 2012. Iron storage proteins are essential for the survival and pathogenesis of Mycobacterium tuberculosis in THP-1 macrophages and the guinea pig model of infection. J Bacteriol 194: 567–575.
143. Reddy PV, Puri RV, Chauhan P, Kar R, Rohilla A, Khera A, Tyagi AK. 2013. Disruption of mycobactin biosynthesis leads to attenuation of Mycobacterium tuberculosis for growth and virulence. J Infect Dis 208: 1255–1265.
144. Remuiñán MJ, Pérez-Herrán E, Rullás J, Alemparte C, Mar-tínez-Hoyos M, Dow DJ, Afari J, Mehta N, Esquivias J, Jiménez E, et al. 2013. Tetrahydropyrazolo[1,5-a]pyrim-idine-3-carboxamide and N-benzyl-6’,7’-dihydrospiro-[piperidine-4,4’-thieno[3,2-c]pyran] analogues with bactericidal efficacy against Mycobacterium tuberculosis targeting MmpL3. PLoS ONE 8: e60933.
145. Rengarajan J, Bloom BR, Rubin EJ. 2005. Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages. Proc Natl Acad Sci 102: 8327–8332.
146. Rhee KY, de Carvalho LP, Bryk R, Ehrt S, Marrero J, Park SW, Schnappinger D, Venugopal A, Nathan C. 2011. Centralcarbon metabolism in Mycobacterium tuberculosis: An unexpected frontier. Trends Microbiol 19: 307–314.
147. Rodriguez GM. 2006. Control of iron metabolism in Myco-bacterium tuberculosis. Trends Microbiol 14: 320–327.
148. Rodriguez GM, Smith I. 2006. Identification of an ABC transporter required for iron acquisition and virulence in Mycobacterium tuberculosis. J Bacteriol 188: 424–430.
149. Rustad TR, Harrell MI, Liao R, Sherman DR. 2008. The enduring hypoxic response of Mycobacterium tuberculosis. PLoS ONE 30: e1502.
150. Salomon CE, Schmidt LE. 2012. Natural products as leads for tuberculosis drug development. Curr Top Med Chem 12: 735–765.
151. Sarathy JP, Dartois V, Lee EJ. 2012. The role of transport mechanisms in Mycobacterium tuberculosis drug resistance and tolerance. Pharmaceuticals (Basel) 5: 1210–1235.
152. Sassetti CM, Rubin EJ. 2003. Genetic requirements for my-cobacterial survival during infection. Proc Natl Acad Sci 100: 12989–12994.
153. Sassetti CM, Boyd DH, Rubin EJ. 2003. Genes required for mycobacterial growth defined by high density mutagen-esis. Mol Microbiol 48: 77–84.
154. Schafer G, Guler R, Murray G, Brombacher F, Brown GD. 2009. The role of scavenger receptor B1 in infection with Mycobacterium tuberculosis in a murine model. PLoS ONE 4: e8448.
155. Scherman MS, North EJ, Jones V, Hess TN, Grzegorzewicz AE, Kasagami T, Kim IH, Merzlikin O, Lenaerts AJ, Lee RE, et al. 2012. Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity invitro and for better physical chemical properties for bioavail-ability. Bioorg Med Chem 20: 3255–3262.
156. Schmitt EK, Riwanto M, Sambandamurthy V, Roggo S, Mi-ault C, Zwingelstein C, Krastel P, Noble C, Beer D, Rao SP, et al. 2011. The natural product cyclomarin kills Myco-bacterium tuberculosis by targeting the ClpC1 subunit of the caseinolytic protease. Angew Chem Int Ed Engl 50: 5889–5891.
157. Schnappinger D, Ehrt S, Voskuil MI, Liu Y, Mangan JA, Monahan IM, Dolganov G, Efron B, Butcher PD, Nathan C, et al. 2003. Transcriptional adaptation of Mycobacte-rium tuberculosis within macrophages: Insights into the phagosomal environment. J Exp Med 198: 693–704.
158. Senaratne RH, Sidders B, Sequeira P, Saunders G, Dunphy K, Marjanovic O, Reader JR, Lima P, Chan S, Kendall S, et al. 2008. Mycobacterium tuberculosis strains disrupted in mce3 and mce4 operons are attenuated in mice. J Med Microbiol 57: 164–170.
159. Sharma V, Sharma S, Hoener zu Bentrup K, McKinney JD, Russell DG, Jacobs WR Jr, Sacchettini JC. 2000. Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis. Nat Struct Biol 7: 663–668.
160. Sherman DR, Voskuil M, Schnappinger D, Liao R, Harrell MI, Schoolnik GK. 2001. Regulation of the Mycobacteri-um tuberculosis hypoxic response gene encoding a-crys-tallin. Proc Natl Acad Sci 98: 7534–7539.
161. Sherrid AM, Rustad TR, Cangelosi GA, Sherman DR. 2010. Characterization of a Clp protease gene regulator and the reaeration response in Mycobacterium tuberculosis. PLoS ONE 5: e11622.
162. Shi S, Ehrt S. 2006. Dihydrolipoamide acyltransferase is critical for Mycobacterium tuberculosis pathogenesis. Infect Immun 74: 56–63.
163. Shirude PS, Madhavapeddi P, Naik M, Murugan K, Shinde V, Nandishaiah R, Bhat J, Kumar A, Hameed S, Holdgate G, et al. 2013. Methyl-thiazoles: A novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis. J Med Chem 56: 8533–8542.
164. Siegrist MS, Unnikrishnan M, McConnell MJ, Borowsky M, Cheng TY, Siddiqi N, Fortune SM, Moody DB, Rubin EJ. 2009. Mycobacterial Esx-3 is required for mycobactin-mediated iron acquisition. Proc Natl Acad Sci 106: 18792–18797.
165. Silvestre HL, Blundell TL, Abell C, Ciulli A. 2013. Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery. Proc Natl Acad Sci 110: 12984–12989.
166. Singh SB, Young K, Miesel L. 2011. Screening strategies for discovery of antibacterial natural products. Expert Rev Anti Infect Ther 9: 589–613.
167. Singh R, Munjunatha U, Boshoff HI, Ha YH, Niyomratta-nakit P, Ledwidge R, Dowd CS, Lee IY, Kim P, Zhang L, et al. 2008. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322: 1392–1395.
168. Siroy A, Mailaender C, Harder D, Koerber S, Wolschendorf F, Danilchanka O, Wang Y, Heinz C, Niederweis M. 2008. Rv1698 of Mycobacterium tuberculosis represents a new class of channel-forming outer membrane proteins. J Biol Chem 283: 17827–17837.
169. Small JL, Park SW, Kana BD, Ioerger TR, Sacchettini JC, Ehrt S. 2013. Perturbation of cytochrome c maturation reveals adaptability of the respiratory chain in Mycobacterium tuberculosis. MBio 4: e0047513.
170. Smith CV, Huang CC, Miczak A, Russell DG, Sacchettini JC, Höner zu Bentrup K. 2003. Biochemical and structural studies of malate synthase from Mycobacterium tuberculosis. J Biol Chem 278: 1735–1743.
171. Stanley SA, Grant SS, Kawate T, Iwase N, Shimizu M, Wivagg C, Silvis M, Kazyanskaya E, Aquadro J, Golas A, et al. 2012. Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. ACS Chem Biol 7: 1377–1384.
172. Stanley SA, Kawate T, Iwase N, Shimizu M, Clatworthy AE, Kazyanskaya E, Sacchettini JC, Ioerger TR, Siddiqi NA, Minami S, et al. 2013. Diarylcoumarins inhibit mycolic acid biosynthesis and kill Mycobacterium tuberculosis by targeting FadD32. Proc Natl Acad Sci 110: 11565–11570.
173. Steinmetz H, Irschik H, Kunze B, Reichenbach H, Höfle G, Jansen R. 2007. Thuggacins, macrolide antibiotics active against Mycobacterium tuberculosis: Isolation from myx-obacteria, structure elucidation, conformation analysis and biosynthesis. Chemistry 13: 5822–5832.
174. Tahlan K, Wilson R, Kastrinsky DB, Arora K, Nair V, Fischer E, Barnes SW, Walker JR, Alland D, Barry CE III, et al. 2012. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 56: 1797–1809.
175. Tarcsay Á, Keserú GM. 2013. Contributions of molecular properties to drug promiscuity. J Med Chem 56: 1789–1795.
176. Thomas ST, VanderVen BC, Sherman DR, Russell DG, Sampson NS. 2011. Pathway profiling in Mycobacterium tuberculosis: Elucidation of cholesterol-derived catabolite and enzymes that catalyze its metabolism. J Biol Chem 286: 43668–43678.
177. Tian J, Bryk R, Shi S, Erdjument-Bromage H, Tempst P, Nathan C. 2005. Mycobacterium tuberculosis appears to lack alpha-ketoglutarate dehydrogenase and encodes py-ruvate dehydrogenase in widely separated genes. Mol Mi-crobiol 57: 859–868.
178. Timm J, Post FA, Bekker LG, Walther GB, Wainwright HC, Manganelli R, Chan WT, Tsenova L, Gold B, Smith I, et al. 2003. Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients. Proc Natl Acad Sci 100: 14321–14326.
179. Truong NB, Pham CV, Doan HT, Nguyen HV, Nguyen CM, Nguyen HT, Zhang HJ, Fong HH, Franzblau SG, Soejarto DD, et al. 2011. Antituberculosis cycloartane triterpe-noids from Radermachera boniana. J Nat Prod 74: 1318–1322.
180. Tullius MV, Harmston CA, Owens CP, Chim N, Morse RP, McMath LM, Iniguez A, Kimmey JM, Sawaya MR, Whitelegge JP, et al. 2011. Discovery and characterization of a unique mycobacterial heme acquisition system. Proc Natl Acad Sci 108: 5051–5056.
181. Van der Geize R, Yam K, Heuser T, Wilbrink MH, Hara H, Anderton MC, Sim E, Dijkhuizen L, Davies JE, Mohn WW, et al. 2007. A gene cluster encoding cholesterol catabolism in a soil actinomycete provides insight into Mycobacterium tuberculosis survival in macrophages. Proc Natl Acad Sci 104: 1947–1952.
182. Venugopal A, Bry kR, Shi S, Rhee K, Rath P, Schnappinger D, Ehrt S, Nathan C. 2011. Virulence of Mycobacterium tuberculosis depends on lipoamide dehydrogenase, a member of three multienzyme complexes. Cell Host Microbe 9: 21–31.
183. Via LE, Lin PL, Ray SM, Carrillo J, Allen SS, Eum SY, Taylor K, Klein E, Manjunatha U, Gonzales J, et al. 2008. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun 76: 2333–2340.
184. Warman AJ, Rito TS, Fisher NE, Moss DM, Berry NG, O’Neill PM, Ward SA, Biagini GA. 2013. Antitubercular pharmacodynamics of phenothiazines. J Antimicrob Che-mother 68: 869–880.
185. Watanabe S, Zimmermann M, Goodwin MB, Sauer U, Barry CE III, Boshoff HI. 2011. Fumarate reductase activity maintains an energized membrane in anaerobic Myco-bacterium tuberculosis. PLoS Pathog 7: e1002287.
186. Wei JR, Krishnamoorthy V, Murphy K, Kim JH, Schnap-pinger D, Alber T, Sassetti CM, Rhee KY, Rubin EJ. 2011. Depletion of antibiotic targets has widely varying effects on growth. Proc Natl Acad Sci 108: 4176–4181.
187. Weinberg ED. 1999. Iron loading and disease surveillance. Emerg Infect Dis 5: 346–352.
188. Weinstein EA, Yano T, Li LS, Avarbock D, Avarbock A, Helm D, McColm AA, Duncan K, Lonsdale JT, Rubin H. 2005. Inhibitors of type II NADH:menaquinone oxidoreduc-tase represent a class of antitubercular drugs. Proc Natl Acad Sci 102: 4548–4553.
189. Wells RM, Jones CM, Xi Z, Speer A, Danilchanka O, Door-nbos KS, Sun P, Wu F, Tian C, Niederweis M. 2013. Discovery of a siderophore export system essential for virulence of Mycobacterium tuberculosis. PLoS Pathog 9: e1003120.
190. Woong Park S, Klotzsche M, Wilson DJ, Boshoff HI, Eoh H, Manjunatha U, Blumenthal A, Rhee K, Barry CE III, Aldrich CC, et al. 2011. Evaluating the sensitivity of My-cobacterium tuberculosis to biotin deprivation using regulated gene expression. PLoS Pathog 7: e1002264.
191. Wright GD. 2014. Something old, something new: Revisiting natural products in antibiotic drug discovery. Can J Microbiol 60: 147–154.
192. Xuequan L, Zhou R, Sharma I, Li X, Kumar G, Swaminathan S, Tonge PF, Tan DS. 2012. Stable analogues of OSB-AMP: Potent inhibitors of MenE, the o-succinylben-zoate-CoA synthetase from bacterial menaquinone. Biosynthesis. Chembiochem 13: 129–136.
193. Yam KC, D’Angelo I, Kalscheuer R, Zhu H, Wang JX, Snieckus V, Ly LH, Converse PJ, Jacobs WR Jr, Strynadka N, et al. 2009. Studies of a ring-cleaving dioxygenase illuminate the role of cholesterol metabolism in the path-ogenesis of Mycobacterium tuberculosis. PLoS Pathog 5: e1000344.
194. Yang X, Gao J, Smith I, Dubnau E, Sampson NS. 2011. Cholesterol is not an essential source of nutrition for Mycobacterium tuberculosis during infection. J Bacteriol 193: 1473–1476.
195. Yano T, Kassovska-Bratinova S, Teh JS, Winkler J, Sullivan K, Isaacs A, Schechter NM, Rubin H. 2011. Reduction of clofazimine by mycobacterial type 2 NADH:quinone ox-idoreductase: A pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem 286: 10276–10287.
196. Yokokawa F, Wang G, Chan WL, Ang SH, Wong J, Ma I, Rao SPS, Manjunatha U, Lakshminarayana SB, Herve M, et al. 2013. Discovery of tetrahydropyrazolopyrimidine car-boxamide derivatives as potent and orally active novel anti-tubercular agents. ACS Chem Lett 4: 451–455.
197. Zhang Y, Wade MM, Scorpio A, Zhang H, Sun Z. 2003. Mode of action of pyrazinamide: Disruption of Mycobac-terium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother 52: 790–795.
198. Zhang YJ, Ioerger TR, Huttenhower C, Long JE, Sassetti CM, Sacchettini JC, Rubin EJ. 2012. Global assessment of genomic regions required for growth in Mycobacteri-um tuberculosis. PLoS Pathog 8: e1002946.